Search results for "HOMA"

showing 10 items of 956 documents

Cytokines in the pathophysiology and treatment of chronic B-cell malignancies

1995

Chronic B-cell malignancies are characterized by accumulation of transformed B cells of low proliferative index in lymphatic and extralymphatic tissues. Cytokines do not appear to play a role in the primary step of transformation. However, proliferation as well as inhibition of apoptosis of malignant B cells can readily be explained by cytokine effects. Clinical trials of interferons (IFN) and interleukin-2 alone or in combination have been performed in patients with hairy cell leukemia (HCL), CLL, and low- and intermediate-grade non-Hodgkin's lymphoma. While IFN alpha became standard therapy of HCL, responses in other entities were variable, ranging from 0 to 70% in selected populations. C…

B-LymphocytesLeukemia Hairy CellChemotherapyLeukemiabusiness.industryLymphoma Non-Hodgkinmedicine.medical_treatmentChronic lymphocytic leukemiaHematologyGeneral MedicineImmunotherapymedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphomaLymphatic systemCytokinemedicine.anatomical_structureImmunologymedicineCytokinesHumansHairy cell leukemiabusinessB cellAnnals of Hematology
researchProduct

Formation et insertion des apprentis de niveau V, quelle relation rétablir ?

1990

International audience

BEPEmploi des jeunes[SHS.EDU]Humanities and Social Sciences/Education[SHS.EDU] Humanities and Social Sciences/EducationAccès à l'emploiInsertion professionnelleNiveau VRelation formation-emploiCAP[SHS]Humanities and Social SciencesApprentiFormation technique courteChomage des jeunesEnseignement secondaire[SHS] Humanities and Social SciencesFranceComputingMilieux_MISCELLANEOUS
researchProduct

Religious spaces as continually evolving modernities: Forms of encounter with modernity in Christian Orthodoxy and Islam

2022

The present study deals with the encounter with modernity in two neighbouring religious spaces: Christian Orthodoxy and Islam. Relying on Eisenstadt’s theory about multiple modernities and on its further developments by Thomas Mergel and Kristina Stoeckl, Islamic and Christian-Orthodox dynamics in relation to the challenges of modernity are examined under two aspects: first, the decoupling between religion and culture as elaborated by Olivier Roy, and second, the development of modernist and fundamentalist currents as phenomena of modernity. The study contributes to the sketching of the profile of Islamic and the Christian-Orthodox modernities, pointing both to some of the commonalities and…

BS1-2970media_common.quotation_subjectorthodoxy; Islam; multiple modernities; second modernity; religion and modernity; religion and culture; fundamentalism; Kristina Stoeckl; Olivier Roy; Thomas Bauer.religion and modernityolivier royOrthodoxyPractical Theologythomas bauerfundamentalismFundamentalismreligion and cultureSociologyRelation (history of concept)media_commonorthodoxykristina stoecklModernitySocial changeReligious studiesIslamislamSecond modernitysecond modernitymultiple modernitiesBV1-5099AestheticsThe BibleOptimal distinctiveness theoryHTS Teologiese Studies / Theological Studies
researchProduct

La voie des idées, de Descartes à Hume

2015

International audience; Lorsque Descartes fait de la connaissance de l'esprit humain la principale tâche de la philosophie, il lui applique l'idée moderne de la science comme connaissance certaine et évidente. Durant les 150 ans qui suivront, aucun penseur ne reniera cette étincelle cartésienne. Dans son sillage mais aussi contre elle, dans le ciel de la philosophie apparaît une constellation de penseurs de premier ordre : Pascal, Hobbes, Spinoza, Malebranche, Leibniz, Locke, Berkeley, Hume. La recherche philosophique accompagnant la "révolution scientifique" commencée avec Galilée s'engage alors dans "la voie des idées". C'est donc sur cette voie que Pierre Guenancia nous entraîne, soulign…

Baruch Spinoza (1632-1677)Idée (philosophie)[SHS.PHIL]Humanities and Social Sciences/PhilosophyBlaise Pascal (1623-1662)Thomas Hobbes (1588-1679)John Locke (1632-1704)René Descartes (1596-1650)Gottfried Wilhelm Leibniz (1646-1716)[SHS.PHIL] Humanities and Social Sciences/Philosophy[ SHS.PHIL ] Humanities and Social Sciences/PhilosophyCritique et interprétationPhilosophie moderneDavid Hume (1711-1776)Nicolas de Malebranche (1638-1715)
researchProduct

Entre l’admiration et la culpabilité : aspects de l’amitié dans les "Mémoires d’une jeune fille rangée"

2017

The character of Elisabeth Mabille, a childhood friend nicknamed “Zaza” becomes symbolic in Simone de Beauvoir’s Memoirs of a Dutiful Daughter. Her influence on the writer and her views seems decisive. For the latter, the literary recreation of her friend is a kind of catharsis. Beauvoir transposes the tragic story of Mabille to show the complexity of their relationship and the origin of her calling to be a writer. Through an autobiographical perspective she “resurrects” the prematurely deceased friend to rehabilitate herself and make up for her neglect. This portrayal of Zaza highlights the multidimensionality of friendship and courage of a young woman who paid the highest price in her fig…

Beauvoirfriendshipcourageemancipationcombathomageautobiography
researchProduct

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

BendamustineAdultMalemedicine.medical_specialtyPhases of clinical researchNeutropeniaGastroenterologyDisease-Free SurvivalDrug Administration ScheduleSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicineInternal medicinefirst-line therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineBendamustine HydrochlorideHumansSplenic marginal zone lymphomabendamustineAgedbusiness.industrySplenic NeoplasmsHematologyLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseLymphomaimmunochemotherapyRegimenTreatment Outcome030220 oncology & carcinogenesisbendamustine; first-line therapy; immunochemotherapy; rituximab; Splenic Marginal Zone Lymphoma; HematologySplenectomyRituximabFemaleSplenic Marginal Zone LymphomaNeoplasm Recurrence LocalbusinessRituximabFebrile neutropenia030215 immunologymedicine.drugBritish journal of haematology
researchProduct

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multice…

2006

Abstract Purpose: Bendamustine is a new anti-lymphoma agent with promising activity. Based on a preceeding phase I study the current trial explored Bendamustine in combination with Mitoxantrone and Rituximab (BMR) in patients with relapsed or refractory indolent lymphomas. Patients and Methods: Patients with relapsed or refractory symptomatic stage III/IV indolent lymphomas with or without prior treatment with Rituximab were eligible. Therapy consisted of Bendamustine 90 mg/m2 days 1+2, Mitoxantrone 10 mg/m2 day 1, Rituximab 375 mg/m2 day 8. Treatment was repeated on day 29 for a total of 4 cycles. Results: Between 04/03 and 07/04 62 patients were recruited from 24 participating institution…

BendamustineMitoxantronemedicine.medical_specialtybusiness.industryImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyLymphomaSurgeryLeukocytopeniaInternal medicinemedicineHairy cell leukemiaRituximabProgression-free survivalbusinessmedicine.drugBlood
researchProduct

ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R)…

2021

Context Tafasitamab+LEN, a chemotherapy-free, novel treatment for R/R DLBCL, demonstrated efficacy in ASCT-ineligible patients in the single-arm Phase II L-MIND study (NCT02399085). Objective To compare outcomes in patients treated with tafasitamab+LEN in the L-MIND study with matched patient populations treated with commonly administered NCCN-/ESMO-recommended therapies for non-transplant-eligible patients with R/R DLBCL in routine clinical practice. Design RE-MIND2 (NCT04150328) is an observational, retrospective cohort study. The L-MIND tafasitamab+LEN cohort was matched with RE-MIND2 patients using estimated propensity score-based 1:1 nearest neighbor matching balanced for nine patient …

BendamustineOncologyCancer Researchmedicine.medical_specialtybusiness.industryContext (language use)Retrospective cohort studyHematologymedicine.diseaseOncologyInternal medicineCohortmedicineClinical endpointRituximabbusinessDiffuse large B-cell lymphomamedicine.drugLenalidomideClinical Lymphoma Myeloma and Leukemia
researchProduct

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/I…

2016

Abstract Background: mTOR inhibition has been shown to be effective in various subtypes of malignant lymphomas (Smith et al, JCO 2010). Furthermore, in relapsed MCL a phase III trial demonstrated superiority of Temsirolimus to chemotherapy. Although novel treatment options as Ibrutinib have changed the treatment landscape for MCL, no curative potential could be shown for this approach and novel concepts continue to be needed. Several trials provided promising results when Temsirolimus is combined with agents like Rituximab (Ansell et al, Lancet Oncology 2011) or chemoimmunotherapy, as shown in part I (phase I) of the reported trial (Hess, Leukemia, 2015). We now report the final analysis of…

BendamustineOncologymedicine.medical_specialtyImmunologyFollicular lymphoma02 engineering and technologyBiochemistry03 medical and health sciences020210 optoelectronics & photonics0302 clinical medicineMedian follow-upChemoimmunotherapyInternal medicine0202 electrical engineering electronic engineering information engineeringMedicinebusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimenTemsirolimusRegimen030220 oncology & carcinogenesisRituximabbusinessmedicine.drugBlood
researchProduct

Splenic marginal zone lymphoma.

2002

Splenic marginal zone lymphoma (SMZL) is a specific low-grade small B-cell lymphoma that is incorporated in the World Health Organization classification. Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern of involvement of various organs, especially bone marrow, and relative indolent course. Tumor progression with increase of blastic forms and aggressive behavior are observed in a minority of patients. Molecular and cytogenetic studies have shown heterogeneous results probably because of the lack of standardized diagnostic criteria. To date, no definitive therapy has been established. Therapeutic options include treatment absten…

BendamustinePathologymedicine.medical_specialtyLymphoma B-CellLymphocytosismedicine.medical_treatmentImmunologySplenectomyBiochemistryImmunophenotypingDiagnosis DifferentialImmunophenotypingMedicineAnimalsHumansSplenic marginal zone lymphomabusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsCell BiologyHematologymedicine.diseaseLymphomaTumor progressionCytogenetic AnalysisRituximabmedicine.symptombusinessmedicine.drugBlood
researchProduct